Press Releases Femasys Inc.

Equities

FEMY

US31447E1055

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-15 EDT			5-day change	1st Jan Change
1.33 ^USD	-3.62%		-4.32%	+36.41%

05-09	Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-09	Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update	05-09	GL
Femasys Expands Commercial Management Team with Addition of Experienced New Hires	05-07	GL
Femasys Expands Commercial Management Team with Addition of Experienced New Hires	05-07	AQ
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives	04-19	AQ
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives	04-18	GL
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	03-28	GL
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	03-28	AQ
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility	03-21	AQ
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape	03-21	GL
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	03-20	GL
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	03-20	AQ
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024	03-13	GL
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	03-06	GL
Femasys FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	02-29	AQ
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	02-28	GL
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	02-28	AQ
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer	02-06	GL
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women	01-26	GL
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology	01-23	GL
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine	12-18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Femasys Inc.

Equities

FEMY

US31447E1055

Press Releases

Filters